Business Wire

PA-BOOMI

31.1.2024 15:01:34 CET | Business Wire | Press release

Share
Boomi Secures Two Patents for AI Innovation

Boomi™, the intelligent integration and automation leader, is proud to announce that it has been granted two new patents by the United States Patent and Trademark Office (USPTO) in the field of Artificial Intelligence (AI). These patents boost Boomi's total patent number to 36, underscoring the company's commitment to innovation and its ongoing efforts to push the boundaries of AI advancement.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240131961796/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Boomi Secures Two Patents for AI Innovation (Graphic: Business Wire)

The newly granted U.S. Patent No. 11,886,965, titled “Artificial-Intelligence-Assisted Construction of Integration Processes,” encompasses the underlying technology of features that allow Boomi’s customers to build integrations based on Boomi suggestions, including Shape Suggest, Quick Start, and more recently, Boomi AI. This innovation addresses the steep learning curve that users, both novice and expert, face when constructing integration processes on an integration platform.

Employing machine learning models – based on a Markov chain or various forms of graph neural networks – facilitates a predictive guidance system for users, enhancing the efficiency and effectiveness of constructing integration processes.

“Our patent award for ‘Artificial-Intelligence-Assisted Construction of Integration Processes’ stands as a notable innovation in the domain of integration platform as a service (iPaaS), and is a testament to the hard work and dedication of our talented team of engineers, scientists, and innovators,” said Ed Macosky, Chief Product and Technology Officer at Boomi. “The contributions through this patent fundamentally challenge the existing paradigms inherent when constructing integration processes. Before this innovation, the construction of integration processes largely relied on the user's expertise and manual inputs using a drag and drop UI, which could be time-consuming and prone to errors, especially for those new to the platform. This AI-driven approach has transitioned construction of integration processes to an intelligent, predictive, and guided task.”

Boomi was also recently granted U.S. Patent No. 11,847,167, titled “System and Method for Generation of Chat Bot System with Integration Elements Augmenting Natural Language Processing and Native Business Rules.” This patent is for a technology solution built on the Boomi platform that creates a series of templatized processes and designs. This allows Boomi customers to build hybrid chatbots that combine rules-based connectivity, natural language processing, Boomi logic, and AI technologies to triage and route requests coming into the chatbot. This technology helped lay the foundation for Retrieval Augmented Generation and demonstrates Boomi’s early innovations in applying AI to integration.

Macosky added, “Achieving these patents reaffirms our commitment to continuous innovation and underscores our position as a leader in the industry. We are excited about the potential impact our AI patents will have for our customers and partners, and we look forward to continuing our mission of driving transformation through intelligent integration and automation.”

Additional Resources

About Boomi
Boomi powers the future of business with intelligent integration and automation. As a category-leading, global software as a service (SaaS) company, Boomi celebrates more than 20,000 global customers and a worldwide network of 800 partners. Organizations turn to Boomi’s award-winning platform to connect their applications, data, and people to accelerate digital transformation. For more information, visit boomi.com.

© 2024 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240131961796/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Merck Collaborates with Versant Ventures to Launch Saturnus Bio to Advance Treatments for Rare Genetic Cardiomyopathies23.6.2026 15:30:00 CEST | Press release

Saturnus Bio is a next-generation precision cardiology company that utilizes targeted gene modulation to address rare mono-genetic cardiomyopathies with significant unmet needThe collaboration will augment Merck’s efforts to pursue precision medicine-defined indicationsNot intended for Canada-, UK- or US-based media Merck, a leading global science and technology company, today announced a strategic research-stage collaboration with Saturnus Bio, a Versant Ventures-founded biotech, aimed at establishing a foundational portfolio in the promising field of rare genetic cardiomyopathies. This partnership aligns with the company’s commitment to address significant unmet medical needs in rare populations through targeted treatments. “Through our partnership with Saturnus Bio, we aim to fast track the development of innovative therapies for genetic cardiomyopathies through precision cardiology, targeting the rare population impacted by these conditions,” said David Weinreich, MD, Head of Resea

Beyond the ‘Dumb Pipe’: How Agentic AI and Sovereign Networks Are Redefining Connectivity23.6.2026 14:46:00 CEST | Press release

The global connectivity market is shifting. With traditional European telecom growth slowing to 2-3% by 2029, businesses must adapt through Agentic AI, critical communications, and digital sovereignty. To remain competitive, operators should move beyond infrastructure toward an API-driven economy. These trends took center stage at Comarch User Group 2026. The conference hosted over 700 partners from 53 countries, including 201 connectivity experts, highlighting how companies can thrive in regulated environments. As telecom growth slows, demand for broader connectivity solutions across satellite, logistics, and critical communications is surging. Operators must abandon the old 4G “dumb pipe” model, where they act merely as network providers charging only for raw data transmission, for an API-driven economy with programmable network quality, securely integrating 5G with new satellite and IoT ecosystems. - Marcin Kaleta, CEO at Comarch Communications Putting Agentic AI in the Driver's Sea

Mary Kay Extends Winning Streak With Fourth Year as #1 in Global Direct Selling Beauty23.6.2026 14:03:00 CEST | Press release

Euromonitor International Recognizes Mary Kay’s Sustained Leadership In Skin Care And Color Cosmetics Mary Kay Inc., the iconic beauty and entrepreneurship company, has once again been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World1 by Euromonitor International, sustaining its legacy of excellence for the fourth consecutive year. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260623487381/en/ Mary Kay Inc., the iconic beauty and entrepreneurship company, for the fourth year in a row has been named the #1 Direct Selling Brand of Skin Care and Color Cosmetics in the World by Euromonitor International. (Image Credit: Mary Kay Inc.) “Earning the #1 global ranking from Euromonitor for the fourth consecutive year comes as a powerful endorsement of the impact of our Independent Beauty Consultants around the world who drive our success every day,” said Ryan Rogers, Chief Executive Officer of Mary Kay

Kobie 2026 Heart of Loyalty Report Reveals Growing Gap Between Consumer Expectations and Brand Loyalty Strategies23.6.2026 14:00:00 CEST | Press release

Global study finds consumers are more ready for AI, more willing to share data, and more motivated by recognition and shared values than many brands realize Kobie, a global leader in loyalty technology and services, today released its 2026 Heart of Loyalty Report, which surveyed both consumers and practitioners, revealing significant gaps between consumer expectations and brand loyalty strategies across AI adoption, data sharing, recognition, advocacy, and community engagement. Kobie's 2026 Heart of Loyalty Report found that: 57% of consumers are willing to engage with AI-powered brand experiences, yet 56% of loyalty practitioners believe customers are not ready for AI. 77% of consumers want recognition from brands, but only 55% feel seen as individuals. 72% of consumers say they would refer a brand without an incentive, yet many referral strategies remain heavily dependent on rewards. Rewards are the strongest driver of willingness to share personal data, yet only 65% of practitioners

Veristat Strengthens Biostatistics, Drug Development Advisory, and People Leadership to Support Growth in Complex Clinical Development23.6.2026 13:05:00 CEST | Press release

Dr. Zhaohui Su and Dr. Gil Fine deepen Veristat’s biostatistics expertise, Scott Tarrant leads Strategic Drug Development Advisory, and Clint Wolfe joins as Chief Human Resources Officer VeristatTM, a global clinical research organization (CRO) and consultancy specializing in complex studies, today announced four strategic leadership hires that advance its mission to accelerate novel therapy approvals in complex disease areas, including cell and gene therapy, oncology, and rare disease. Building on its 30-year foundation in biostatistics and its recent acquisition of the medical writing and regulatory submission business of Certara, Veristat is deepening its scientific expertise and expanding its operational leadership to meet growing client demand. Dr. Zhaohui Su and Dr. Gil Fine join Veristat’s Strategic Drug Development Advisory team in biostatistical leadership roles, collaborating with Scott Tarrant, who has been named Executive Vice President of the team. In addition, Clint Wolfe

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye